Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphoma
Maria Cristina Pirosa(Institute of Oncology Research), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alessio Bruscaggin(Institute of Oncology Research), Luca Mazzucchelli(Istituto Cantonale di Patologia), Salvatore Annunziata(Agostino Gemelli University Polyclinic), Jan Maciej Zaucha(Gdańsk Medical University), Lodovico Terzi di Bergamo(Institute of Oncology Research), Georg Stüssi(Institute of Oncology Research), Adalgisa Condoluci(Ente Ospedaliero Cantonale), Marcello Rodari(Humanitas University), Luigi Maria Larocca(Agostino Gemelli University Polyclinic), Renzo Boldorini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luca Ceriani(St Thomas' Hospital), Joyce Marques de Almeida(Institute of Oncology Research), Eugenio Borsatti(Centro di Riferimento Oncologico), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Pietro Bulian(Centro di Riferimento Oncologico), Michał Kurlapski(University Clinical Centre), Antonio Pinto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Martina Di Trani(Humanitas University), Deborah Piffaretti(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Carmelo Carlo‐Stella(Humanitas University), Simone Bocchetta(Institute of Oncology Research), Stéphane Chauvie(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Claudia Giordano(Federico II University Hospital), Marco Cuzzocrea(Institute of Oncology Research), Anastasios Stathis(Princess Margaret Cancer Centre), Franco Cavalli(Institute of Social and Preventive Medicine), Katia Pini(Institute of Oncology Research), Matin Salehi(SIB Swiss Institute of Bioinformatics), Ilaria Zangrilli(Agostino Gemelli University Polyclinic), B. Gerber(University of Zurich), Vanessa Cristaldi(Humanitas University), Grzegorz Romanowicz(Gdańsk Medical University), S. Hohaus(Agostino Gemelli University Polyclinic), Gabriela Forestieri(Institute of Oncology Research), Valter Gattei(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alden A. Moccia(BC Cancer Agency), Gian Mauro Sacchetti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Armando Santoro(IRCCS Humanitas Research Hospital), Emanuele Zucca(Università della Svizzera italiana), Valeria Spina(Ente Ospedaliero Cantonale), Federico Jauk(Institute of Oncology Research), G. Galimberti(Institute of Oncology Research), Fabrizio Bergesio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791